Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 4/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24378636 | 0.89 | PREP (0.53) | KMT2AOPRD1PREPEPHX2 | |
| SCHEMBL21462327 | 0.85 | OPRD1 (0.49) | KMT2AOPRD1PREPEPHX2F2 | |
| SCHEMBL29444020 | 0.85 | OPRD1 (0.49) | KMT2AOPRD1PREPEPHX2F2 | |
| SCHEMBL31258873 | 0.85 | OPRD1 (0.49) | KMT2AOPRD1PREPEPHX2F2 | |
| SCHEMBL24378516 | 0.84 | OPRD1 (0.48) | KMT2AOPRD1PREPEPHX2F2 | |
| SCHEMBL29731400 | 0.84 | OPRD1 (0.48) | KMT2AOPRD1PREPEPHX2F2 | |
| SCHEMBL30034009 | 0.82 | OPRD1 (0.47) | KMT2AOPRD1PREPEPHX2F2 | |
| SCHEMBL28665306 | 0.82 | OPRD1 (0.48) | KMT2AOPRD1PREPEPHX2F2 | |
| SCHEMBL30366864 | 0.82 | OPRD1 (0.48) | KMT2AOPRD1PREPEPHX2F2 | |
| SCHEMBL28679703 | 0.81 | OPRD1 (0.47) | KMT2AOPRD1PREPEPHX2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4406608-A2 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20240190973-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2024-06-13 | — | — | US | disclosed |
| CN-118085100-A | Camptothecin analogues conjugated to glutamine residues in proteins and uses thereof | 瑞泽恩制药公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4232481-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116406379-A | anti-FGFR 2 antibodies and methods of use thereof | 瑞泽恩制药公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116390771-A | Camptothecin analogues conjugated to glutamine residues in proteins and uses thereof | 瑞泽恩制药公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2022087243-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022087243-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-113905767-A | Traceless linkers and protein conjugates thereof | 里珍纳龙药品有限公司 | 2022-01-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190973-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | FGFR2, FGFR3, FGFR1 | KMT2A 1825/4885OPRD1 4489/4885PREP 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.